Replies

From Inovio Pharmaceuticals information, they are going to start testing in April.

If that looks promising, since their process is different, with an emergency exemption, they can have 1,000,000 doses by the end of the year. Over that would require expansion of capacity/partners to grow the vaccine.

I would assume other vendors, like J&J and Giliad, who have vaccines under development, would have the same time frame.

The plasma method is effective for a short term immunity. It doesn’t seem to incur a long term effectiveness however. But in combination with a vaccine, would work. The problem seems to be obtaining a sufficient volume of cured patients to collect plasma from.

I read, I think on WebMD, that it takes several ‘CC’s of plasma per inoculation. The benefit last for upwards of a year, but not much longer, as I recall.